Bijuva Savings Card: 2026 Eligibility, Terms, and the $35 Claim

The 2026 Bijuva savings card can lower an eligible copay only if you have commercial insurance that covers Bijuva. Mayne Pharma's public card terms do not promise a $35 price. Cash-paying patients are excluded from the commercial card, and Medicare users need a separate Part D alternative coupon with year-end opt-out rules.

Last verified: August 3, 2026 By The HRT Index Editorial Team Editorial research — not medically reviewed by a clinician. Read our medical review policy →

We read the current commercial card, the separate Medicare terms, the manufacturer-linked delivery flyers, and the pages telling you Bijuva costs $35. They do not line up.

One listing still shows a 2024 expiration date for a card that the manufacturer says is valid through December 31, 2026. Another manufacturer-linked flyer advertises a cash price on the front, then excludes cash-paying patients in the fine print on the back.

That gap is what this page is about.

Best for / not for you if

The commercial card is for you if: you have a commercial or healthcare-exchange prescription plan, and that plan covers Bijuva when the pharmacy fills it.

The commercial card is not for you if: you are paying cash, your commercial plan excludes Bijuva, or you have Medicare, Medicaid, TRICARE, VA, IHS, or another excluded government-funded benefit.

Medicare has a different door: a separate Mayne Pharma Part D alternative coupon may apply, but using it means agreeing not to use your Part D benefit for Bijuva through the end of that calendar year.

The key constraint: Mayne's current retail-card terms publish no fixed copay, no $35 guarantee, and no public maximum benefit.

Your situation	Start here	The catch
Commercial plan covers Bijuva	Current Mayne commercial copay card	Deductible, prior authorization, and program reimbursement limits can still affect the price.
Commercial plan does not cover Bijuva	Coverage review, cash-price comparison, or a prescriber discussion	The retail card requires coverage; it cannot create coverage.
Medicare Part D or Medicare Advantage	Separate Mayne Medicare Part D Alternative Coupon Program	You agree not to use Part D for Bijuva through year-end, even if benefits change.
Uninsured or paying cash	Cash coupon or a live quote from a delivery service	The retail commercial card excludes cash-paying patients.
Medicaid, TRICARE, VA, IHS, or another excluded government program	Ask the plan and prescriber about covered options	The commercial card is void for these programs.

Which Bijuva savings card route applies to you?

Mayne Pharma publishes two formal coupon programs with opposite insurance rules, plus manufacturer-linked home-delivery resources. Commercially insured patients whose plans exclude Bijuva and uninsured patients do not meet either formal program's published eligibility rules. The fastest way to stop guessing is to identify your coverage type, confirm whether Bijuva is covered, and then use the lane that actually accepts you.

The four routes — and the gap

Route	Who it is for	What is publicly stated	What can stop it
Commercial retail copay card	Commercial or exchange-plan member whose plan covers Bijuva	Current card is activated, expires December 31, 2026, and reduces eligible out-of-pocket cost	Noncoverage, excluded coverage, deductible, prior authorization, nonparticipating pharmacy, or maximum reimbursement limits
BlinkRx home delivery	A prescriber sends Bijuva to BlinkRx for a delivered-price quote	Mayne's current BlinkRx flyer displays $25 for one covered box, $50 for three covered boxes, and $50 for uncovered or cash-pay patients	The same flyer's fine print requires commercial coverage and excludes cash-paying patients, so the displayed cash/uncovered figure needs a live quote before transfer
Medicare Part D alternative coupon	An eligible Part D or Medicare Advantage enrollee whose plan does not cover Bijuva or whose cost exceeds the published threshold	Reduces out-of-pocket expense after enrollment	Requires a calendar-year opt-out for Bijuva, no TrOOP credit, no HSA/FSA submission, and maximum limits apply
Third-party cash discount	Uninsured patients, noncovered commercial patients, or anyone choosing a cash transaction instead of insurance	GoodRx, SingleCare, and other programs display pharmacy- and channel-specific cash prices	Cannot be stacked with an insurance claim for the same fill; prices vary by prescription, ZIP code, pharmacy, session, and delivery channel
The gap	Commercial plan excludes Bijuva and no acceptable cash or delivery price is available	No current Mayne retail-card route creates coverage	Coverage review, an appeal, or a different FDA-approved prescription may be the only practical paths

Sources: Mayne commercial copay card, Mayne Medicare Part D Alternative Coupon Program, and Mayne's current BlinkRx flyer, all verified August 3, 2026.

Four-question Bijuva savings route check

Answer these in order:

1. What coverage do you have? Commercial/private, Medicare Part D or Medicare Advantage, another government-funded program, or none.
2. Does that plan cover Bijuva today? Yes, no, prior authorization pending, or unknown.
3. Are you Medicare-eligible while enrolled in an employer or retiree prescription benefit? The commercial-card terms specifically exclude that group.
4. Do you want retail pickup or a delivered quote? The commercial retail card and BlinkRx route are not the same transaction.

Then use the result below:

Your answers	Your likely route	What to do next
Commercial + covered	Commercial retail card	Download the current manufacturer PDF and ask the pharmacy for insurance-only and insurance-plus-card prices.
Commercial + covered + delivery preferred	BlinkRx may be worth quoting	If you choose this route, ask the prescriber to send the prescription to BlinkRx; BlinkRx then contacts you with the available price before purchase. Do not rely on the flyer as a guaranteed cash price.
Commercial + not covered	The retail card does not apply	Ask whether the issue is a prior authorization, tier restriction, or formulary exclusion. Compare a normalized cash price while the review is pending.
Part D or Medicare Advantage + no coverage, or cost above Mayne's threshold	Medicare alternative program may apply	Read the opt-out terms and compare the coupon route against lost Part D out-of-pocket credit before enrolling.
Medicaid, TRICARE, VA, IHS, or another excluded government program	Neither Mayne formal coupon is ordinarily available	Ask the plan about covered FDA-approved alternatives and any plan-specific exception process.
Uninsured or paying cash	Cash or delivery-price route	Compare the exact strength, 30-capsule quantity, ZIP code, pharmacy or delivery channel, and date.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

How much will you actually pay with the Bijuva savings card?

We cannot tell you what you will pay with the retail card. Mayne Pharma does not publish a fixed copay, a maximum dollar benefit, or a universal price. The final amount appears only after the pharmacy runs your prescription through your specific insurance plan and applies any eligible card benefit.

Here is the damaging admission, before we ask you to trust anything else on this page:

We cannot tell you what you'll pay with this card. Neither can any page that has not run your exact claim.

The current card says two things instead:

• Eligible patients may have out-of-pocket costs that vary from patient to patient.
• Restrictions and maximum reimbursement limits may apply.

That is all Mayne publishes about the dollar result.

Every page promising a single number is skipping the part where your plan, deductible, prior authorization, pharmacy, quantity, and remaining program benefit decide the answer.

So here is the pivot: "How much?" is not a number you can settle from a headline. "Am I in the right program?" is.

Once you know the right route, you can make the pharmacy run a comparison instead of walking into an ambush.

Why the price moves

Your result can change with:

1. The plan's negotiated Bijuva price
2. Bijuva's formulary tier
3. Whether the plan's pharmacy deductible has been met
4. Copay versus coinsurance
5. Prior-authorization status
6. Strength and quantity
7. Pharmacy or delivery channel
8. The card's undisclosed maximum reimbursement limits

That is why the honest next step is not to trust someone else's copay. It is to get your own three quotes and keep the coverage consequences beside the dollar amount.

Don't plan around a price nobody promised. Use the route check above, then ask the pharmacy for the three comparable prices in the pharmacy section below.

Is the $35 Bijuva savings card price real?

The $35 figure appears on GoodRx, Drugs.com, and WebMDRx, but we could not verify it in Mayne Pharma's current commercial-card document, patient savings page, Medicare form, or 2026 BlinkRx terms. We did not run a claim, so we cannot say whether an eligible transaction currently reaches $35. Mayne does not publicly guarantee it.

This is the heart of the page, so we are going to show our work.

The Bijuva savings card claim audit

Claim published online	Where it appears	What Mayne's current materials say	What you should rely on
"Pay as little as $35"	GoodRx, Drugs.com, WebMDRx	The current commercial card contains no $35 figure; it says patient costs vary and maximum limits apply	Report it only as a secondary-site claim, never as a manufacturer-guaranteed copay
"$75 for insured patients without coverage and cash-paying patients"	GoodRx's manufacturer-coupon module	The current retail card requires commercial coverage and is void for cash-paying patients	Contradicts the current retail-card terms
"Do I need insurance? No"	GoodRx's manufacturer-coupon module	Commercial insurance that covers Bijuva is required	Contradicts the eligibility rule
"Expiration: 12/31/24"	GoodRx's manufacturer-coupon module	The current card expires December 31, 2026	Stale metadata that could make an active card look dead
"Up to 12 uses for 30-day fills; four for 90-day fills"	GoodRx's manufacturer-coupon module	The current card publishes no use count	Unverified against current manufacturer terms
Phone 1-347-442-7919	GoodRx's manufacturer-coupon module	The current InfinityRx help number is 1-888-927-3499	Do not publish the stale number
$50 uncovered or cash-pay through BlinkRx	Front of Mayne's current BlinkRx flyer	The back of the same flyer requires commercial coverage and says the offer is void for cash-paying patients	Internal manufacturer-document conflict; get a live quote before relying on it
$50 through GoodRx Prescription Services	A price sheet still linked from Mayne's HCP support page	The sheet's fine print says the offer expired December 31, 2025	Do not present it as a current 2026 program price

Sources checked August 3, 2026: current Mayne retail card, GoodRx Bijuva page, Drugs.com Bijuva price guide, WebMDRx Bijuva page, BlinkRx flyer, and GoodRx Prescription Services flyer.

What we are not saying

We are not saying $35 is false.

We are not saying that no eligible claim ever adjudicates to $35. We did not run a claim. Drugs.com currently describes the program as reducing eligible costs "as low as $35," and GoodRx and WebMDRx repeat the same number.

What we are saying is narrower and more useful:

Mayne's current public retail-card terms do not promise it. GoodRx's record carries a 2024 expiration date and other terms that conflict with the 2026 card. Your final number is set when the claim runs, not when a page writes a headline.

Notice which direction the stale date cuts. A woman who sees "expired 12/31/24" may decide the card is dead and leave without trying it.

The card is current. The $35 guarantee is not.

Does the Bijuva savings card still work in 2026?

Yes. Mayne Pharma Commercial LLC publishes a current Bijuva commercial copay card administered by InfinityRx. The card is activated and ready to use, expires December 31, 2026, and applies only to eligible commercially insured patients whose plan covers Bijuva at the time of dispensing.

The current card at a glance

What you want to know	What the current card says
Program administrator	InfinityRx on behalf of Mayne Pharma Commercial LLC
Activation	Activated and ready to use
Expiration	December 31, 2026
Help desk	1-888-927-3499
Insurance required	Commercial insurance that covers Bijuva
Healthcare exchange plan	May qualify if the remaining terms are met
Pharmacy	Participating U.S. retail pharmacy
Fixed copay promised	No
Maximum benefit disclosed	No; maximum reimbursement limits apply
Deductible rules	The patient must meet applicable plan requirements
Prior authorization	The patient must meet insurer submission requirements
Insurance product	No; the card says it is not health insurance

Verified from: Mayne's current Bijuva commercial copay card, document code PM-US-BJVA-0086 09/26.

Do you need to sign up?

No separate patient enrollment form appears on the commercial card. It states that it is activated and ready to use.

That is genuinely good news. Download it before you leave home instead of searching for it after the pharmacist quotes you a number.

Why we are not printing the card's processing codes here

The card contains a BIN, PCN, group, and member ID. We verified them, and we are deliberately not turning this page into a permanent copy of them.

Manufacturers can replace cards or processing data. A stale code copied from an article can create a rejection that looks like an eligibility problem.

Use the current manufacturer PDF at the time of your fill.

Get the real card, not a copy. Open the current Bijuva commercial copay card on bijuva.com → Official manufacturer resource. This is not an affiliate link, and The HRT Index earns nothing from it.

Who qualifies for the Bijuva savings card?

You need a commercial prescription plan — potentially including a healthcare-exchange plan — that covers a valid Bijuva prescription when the pharmacist fills it. The offer is void for cash-paying patients, excluded government programs, fully reimbursing plans, and certain Medicare-eligible employer or retiree-plan members.

Read the condition again, because it decides the whole page:

Your plan has to cover Bijuva.

The card reduces an eligible out-of-pocket cost. It does not create formulary coverage where none exists.

The five disqualifying categories in the current card

1. Federal or state-funded programs. The terms list Medicare, Medicare Advantage, Part D, Medigap, Medicaid, TRICARE, VHA, DOD, IHS, and state pharmaceutical-assistance programs among the exclusions.

2. Cash-paying patients. If the prescription is not being processed under eligible commercial coverage, the retail copay card does not apply.

3. Private indemnity or HMO plans that fully reimburse prescription costs. The card has no eligible copay to reduce when the plan already reimburses the full prescription cost.

4. Medicare-eligible individuals enrolled in an employer-sponsored health plan or retiree prescription-drug benefit. This is the quiet clause most summaries miss. Commercial-looking coverage does not automatically make the patient eligible.

5. Any use prohibited, taxed, or restricted by law.

Deductible and prior authorization still apply

The card explicitly says the patient must meet applicable commercial-insurance deductible requirements and prior-authorization submission requirements determined by the insurer.

That means:

• A deductible can still shape the result.
• The card does not bypass a prior authorization.
• A denied or unresolved coverage claim can block the card because the plan is not covering Bijuva at dispensing.

What the HSA/FSA clause actually says

The commercial-card terms prohibit seeking reimbursement for the value received from the copay-card program. They do not state that every remaining dollar you personally pay is automatically ineligible under your HSA or FSA rules.

Ask your account administrator whether the remaining patient-paid amount can be submitted, and never submit the value paid by the card.

The Medicare alternative program is stricter: its participant attestation says no Bijuva out-of-pocket cost under that program will be submitted to an HSA, FSA, insurance plan, or other healthcare-reimbursement account.

Your five-question eligibility check

1. Is this commercial or private prescription coverage?
2. Does the plan cover Bijuva today?
3. Are you outside every government-program and plan-type exclusion?
4. If you are Medicare-eligible, are you outside the excluded employer or retiree-benefit category?
5. Is the prescription being filled at a participating U.S. retail pharmacy?

Five yeses put you in the likely commercial-card lane. Final eligibility is still determined when the transaction is processed.

The insurer call that prevents most surprises

Ask the number on your prescription-benefit card:

1. "Is Bijuva on my formulary, and what tier is it?"
2. "Does it require prior authorization, step therapy, or a formulary exception?"
3. "What would I pay for my exact strength and 30-capsule quantity today?"
4. "How much of my pharmacy deductible remains?"
5. "If I pay cash instead, can I submit the receipt for deductible or out-of-pocket credit?"

Write down the representative's name or reference number, the answer, and the date.

How do you use the Bijuva savings card at the pharmacy?

Present the current card with a valid prescription at a participating U.S. retail pharmacy and have the pharmacist process it with the eligible commercial-insurance claim. The retail card is not a standalone cash coupon. If processing fails, ask for the exact rejection message and call InfinityRx at 1-888-927-3499 while the claim is open.

The transaction only helps if it is set up correctly. Use these six steps.

Step 1 — Open the current card. Use the live manufacturer PDF, not a saved screenshot or copied processing code.

Step 2 — Check the prescription. Confirm your name, strength, quantity, days' supply, prescriber, and refills.

Step 3 — Have commercial insurance run. The retail card requires the plan to cover Bijuva.

Step 4 — Ask the pharmacist to apply the card. Use this script:

"My commercial plan covers Bijuva, and I have the current Mayne Pharma copay card. Could you process it with the required Other Coverage Code and tell me the final cost before you fill it?"

The phrase Other Coverage Code matters because the current card tells the pharmacist that a valid code is required. Naming it gives the pharmacy a concrete processing field to check.

Step 5 — Ask for three comparable prices. Do not compare an insurance copay, a cash coupon, and a delivered offer as though they have identical consequences.

Step 6 — Call while the claim is open. InfinityRx can address card processing at 1-888-927-3499. A rejection code is far more useful while the pharmacist can still see the transaction.

The three prices to request

1. Insurance alone
2. Insurance plus the commercial manufacturer card, if eligible
3. Cash through the exact discount or delivery route you are considering

Then compare four things, not one:

Compare	Why it matters
Final amount due today	The obvious number, but not the only number
Deductible or out-of-pocket credit	A commercial cash purchase is not automatically credited; ask your plan whether a receipt can be submitted
Medicare TrOOP credit	Cash-discount purchases do not count toward the Part D deductible or out-of-pocket maximum; Mayne's Medicare program expressly bars TrOOP credit
Refill, delivery, and quantity terms	A one-time shipped price can be worse than a stable local price if refills or 90-day quantities differ

GoodRx and insurance cannot be applied to the same prescription at the same time. A cash coupon is a separate transaction. You can ask a commercial insurer whether it will accept the receipt for deductible credit, but that credit is not automatic. Medicare says discount-card purchases made instead of Part D do not count toward the Part D deductible or out-of-pocket maximum.

Source: Medicare guidance on Extra Help and discount-card costs.

Printable pharmacy quote sheet

What to record	Quote 1: insurance	Quote 2: insurance + Mayne card	Quote 3: cash or delivery
Strength and quantity
Pharmacy or delivery service
Price due today
Counts toward deductible?
Counts toward Medicare TrOOP?
Prior authorization complete?
Refill or delivery terms
Exact rejection message
Date checked

Before leaving the counter, also record the NDC submitted and the name of the route actually used.

What about mail order and 90-day fills?

The commercial retail-card terms say participating U.S. retail pharmacies. They do not publish a universal mail-order rule, a 90-day benefit, or a current use limit.

BlinkRx is a separate manufacturer-linked delivery route with its own process. Do not assume that BlinkRx pricing proves the retail card works by mail, or that a third-party statement about four 90-day uses is current.

Call InfinityRx at 1-888-927-3499 for the retail card. Get a live BlinkRx quote for the delivery route.

Why did the Bijuva savings card not work?

A rejected or disappointing transaction does not automatically mean the card is dead. The usual failure points are plan noncoverage, an excluded benefit type, unresolved prior authorization, a nonparticipating pharmacy, stale card data, an invalid Other Coverage Code, or a program reimbursement limit. Get the exact response before you pay full price.

"It didn't work" is not a rejection code. It is the beginning of the question.

The Bijuva rejection decoder

What happened	What it can mean	Ask this next
The plan says Bijuva is not covered	The card's core coverage condition is not met, or a coverage review is still unresolved	"Is this a formulary exclusion, a prior-authorization issue, or a tier restriction?"
Prior authorization is required	The insurer has not approved coverage under its clinical criteria	"Has the request been submitted, and what information is still missing?"
The price is high because of the deductible	The plan may be processing the prescription correctly, but the remaining card benefit is not enough to create the price you expected	"What is my insurance-only price, and what is my insurance-plus-card price?"
The coverage type is ineligible	Medicare, Medicaid, TRICARE, VA, IHS, another government program, or an excluded Medicare-eligible employer or retiree benefit may be showing	"What benefit type is the claim identifying?"
The pharmacy cannot process the card	The location may not participate, or the secondary claim may be entered incorrectly	"Does this location accept manufacturer copay cards, and was a valid Other Coverage Code used?"
The card shows old information	A saved card, copied code, or third-party listing may be stale	"What expiration date and help-desk number are showing?"
A maximum-benefit message appears	The program's unpublished reimbursement limit may have been reached	"What exact limit or response did the adjudication return?"
Refill too soon or quantity limit	The timing or quantity may not match the plan or program rules	"What is the next covered fill date, and what quantity was submitted?"

The current commercial card requires a valid Other Coverage Code and directs pharmacy processing questions to InfinityRx. It also says maximum reimbursement limits apply without publishing the amount.

Work through the problem in this order

1. Does the plan cover Bijuva today?
2. Is the coverage type eligible for the commercial card?
3. Is prior authorization complete?
4. What did insurance alone return?
5. Is the current manufacturer PDF being used?
6. Was a valid Other Coverage Code entered?
7. What is the exact rejection message?
8. Has the pharmacy or patient called InfinityRx while the claim is open?

Rejected at the counter? Get the code before you leave. Call InfinityRx at 1-888-927-3499 while the pharmacist can still see the claim. Official program help desk. This is not an affiliate link.

Can you use a Bijuva coupon without insurance?

You cannot use the current commercial retail card as a cash-paying patient. An uninsured patient can compare third-party cash discounts and request a live BlinkRx delivery quote, but the current BlinkRx flyer contradicts itself by advertising a cash price on the front and excluding cash-paying patients in the fine print. Do not transfer a prescription based on the headline alone.

We wish this were a softer answer. It is not.

GoodRx's manufacturer-coupon module says insurance is not required and lists a $75 cash or noncovered price. Mayne's current retail-card document says the patient must have commercial coverage of Bijuva and says the offer is void for a cash-paying patient.

For the retail card, the manufacturer's current terms control its own program.

Did we find a separate Bijuva patient assistance program?

As of August 3, 2026, Mayne's public Bijuva resources list the commercial retail card, the Medicare Part D alternative coupon, BlinkRx, and a GoodRx Prescription Services flyer. We did not find a separate income-based Bijuva patient assistance program in those current public resources.

Drugs.com's assistance directory also says no patient assistance program was found, but that is a secondary directory—not proof that Mayne could never add or offer another route. Call 1-888-927-3499 before treating the absence as permanent.

What cash prices did we actually observe?

These are dated screen prices, not checkout guarantees. They are useful only when the prescription and channel match.

Source checked August 3, 2026	Prescription shown	Displayed price	What the number means
GoodRx home delivery	Bijuva 1 mg/100 mg, 30 capsules	$50.00	Adelaide Apothecary delivery with free shipping on the live GoodRx page
GoodRx dosage table	Bijuva 0.5 mg/100 mg or 1 mg/100 mg, 30 capsules	$85.00	Displayed GoodRx price before a location-specific pharmacy checkout
SingleCare	Bijuva 1 mg/100 mg, 30 capsules	$243.92, or $240.92 after a displayed one-time $3 member bonus	Location-dependent coupon listing; the bonus is not the recurring base price
BlinkRx manufacturer flyer	Bijuva, one month	$50.00 for uncovered or cash pay on the front	Fine print on the back excludes cash-paying patients, so a live quote is required

Sources: GoodRx Bijuva pricing, SingleCare Bijuva pricing, and Mayne's BlinkRx flyer.

The spread is real. The comparison is not automatically apples to apples.

A delivered offer, a local pharmacy coupon, and a one-time member-bonus price can have different refill rules, transfer steps, delivery timing, and insurance consequences. Normalize all five fields before deciding:

1. Strength
2. Quantity
3. ZIP code
4. Pharmacy or delivery channel
5. Date and refill terms

Compare the exact prescription, not the biggest discount percentage. Use the pharmacy quote sheet above and record what each route costs today, what it credits toward your plan, and what happens at the next fill.

What if your insurance does not cover Bijuva?

The commercial retail card cannot create coverage when a plan excludes Bijuva. Your practical routes are to identify whether the problem is prior authorization or a true formulary exclusion, pursue the plan's review process with accurate clinical documentation, compare a normalized cash or delivery price, or ask the prescriber about another FDA-approved option.

This is the coverage gap. It is also why the name on the insurance card does not settle the question.

The same drug can be excluded on one formulary and covered on another

We verified two 2026 examples from primary plan documents:

2026 formulary document	Bijuva status in that document	What it does—and does not—tell you
Express Scripts National Preferred Formulary Exclusions, EXCL-NPF-26, dated April 1, 2026	Excluded; the document lists estradiol/norethindrone acetate and ethinyl estradiol/norethindrone acetate as preferred alternatives	Shows one national template, not the terms of every Express Scripts-administered employer plan
Optum Rx 2026 Premium Formulary booklet	Tier 3	Shows coverage in one identified formulary, not a promise about every Optum-administered plan or the amount any member pays

Sources: Express Scripts 2026 National Preferred Formulary Exclusions and Optum Rx 2026 Premium Formulary.

Excluded on one. Tier 3 on another. Same drug, same year.

Your own plan document and claim response control your answer.

What can a prior-authorization policy require?

Mass General Brigham Health Plan's commercial and exchange Bijuva policy, effective September 1, 2025, gives one concrete example. Its standard criteria require a diagnosis of moderate-to-severe menopausal vasomotor symptoms and an inadequate response, intolerance, or contraindication to estrogen and progesterone taken concurrently as separate agents.

The same policy has a separate continuation pathway for members new to the plan. For that pathway, treatment obtained as samples or through a manufacturer patient-assistance program does not count as the required current treatment history.

That is one plan's policy, not a national rule.

Source: Mass General Brigham Health Plan Bijuva prior-authorization policy.

The documentation move that is safe and useful

Do not start, stop, or switch medication merely to manufacture a coverage record.

Ask the prescriber to document what is already true:

• The exact diagnosis and symptoms supporting the prescription
• Treatments you actually used
• Your actual response, intolerance, or contraindication
• Why Bijuva was selected
• The plan's stated denial reason
• The clinical reason for the requested exception

That is not gaming the system. It is making sure the plan receives the real record instead of a vague sentence that cannot satisfy its own policy.

The questions to ask after a denial

Ask the insurer:

"Is this a prior-authorization denial, a step requirement, or a nonformulary exclusion? Please send me the written criteria and appeal instructions for my exact plan."

Ask the prescriber:

"Can you review the denial, document my actual treatment history and clinical reason for Bijuva, and tell me whether an appeal or a different FDA-approved option is the better route?"

Ask the pharmacy:

"While the review is pending, what is the exact cash price for my strength and 30-capsule quantity through each discount route?"

For a broader comparison of insurance and self-pay routes, see The HRT Index's 2026 HRT cost guide.

Can you use the Bijuva savings card with Medicare?

No. The commercial Bijuva card is void for Medicare, Medicare Advantage, and Part D. Mayne has a separate Medicare Part D Alternative Coupon Program for eligible Part D or Medicare Advantage enrollees, but enrollment requires opting out of using the prescription benefit for Bijuva through the end of that calendar year.

Two Mayne programs. Opposite eligibility. The Medicare one is not a normal copay card layered on top of Part D.

The two Mayne programs side by side

	Commercial retail copay card	Medicare Part D Alternative Coupon Program
Who it is for	Eligible commercial or exchange-plan patient whose plan covers Bijuva	Eligible Part D or Medicare Advantage enrollee
Public entry condition	Commercial plan covers Bijuva at dispensing	Plan does not cover Bijuva, or insured out-of-pocket cost exceeds the quantity threshold
Fixed price published	No	No
Insurance used for the Bijuva fill	Yes	No; the participant agrees to purchase Bijuva outside the Part D benefit
What the patient gives up	Cannot seek reimbursement for the value received from the card	No Part D claim, no insurance/HSA/FSA reimbursement, and no true out-of-pocket credit for Bijuva under the program
End date	December 31, 2026 unless amended or rescinded	End of the calendar year in which enrollment is approved
Help number	1-888-927-3499	1-888-927-3499

The published Medicare thresholds

You may meet the public entry condition when the Part D or Medicare Advantage plan does not cover Bijuva, or when your insured out-of-pocket amount exceeds:

Quantity	Threshold
30 capsules	More than $50
60 capsules	More than $100
90 capsules	More than $150

The trigger is published. The resulting coupon price is not. Maximum reimbursement limits apply.

What you agree to when you enroll

The current enrollment page requires the participant to attest that she will:

1. Opt out of using prescription insurance for Bijuva for the remainder of the calendar year
2. Stop purchasing Bijuva through Part D for the rest of that year, even if benefits change
3. Notify the plan using Mayne's opt-out letter
4. Not submit Bijuva costs to an insurance plan, HSA, FSA, or another healthcare-reimbursement account
5. Not seek true out-of-pocket credit under a government program for the medication
6. Not combine the program with another coupon, free trial, discount card, prescription savings card, or other offer

The program also says maximum limits apply and the patient pays additional costs after those limits are reached.

Source: Mayne Pharma's Bijuva Medicare Part D Alternative Coupon Program.

The $2,100 Part D tradeoff

Medicare's 2026 handbook sets the annual out-of-pocket cap for covered Part D drugs at $2,100. After the cap is reached, the enrollee pays no copayment or coinsurance for covered Part D drugs for the rest of the calendar year.

Bijuva spending through Mayne's alternative program does not receive true out-of-pocket credit. That creates a real tradeoff:

• A lower Bijuva price outside Part D may reduce today's pharmacy bill.
• The same transaction does not move you toward the $2,100 cap.
• That lost credit matters more when you also use other expensive covered Part D medications.

Do not reduce this decision to one Bijuva price. Compare the coupon result with the value of the Part D credit you give up.

Source: Medicare & You 2026.

What if you receive Extra Help?

Medicare says 2026 costs for people who qualify for Extra Help will generally be no more than $5.10 per generic and $12.65 per brand-name drug at a participating plan pharmacy.

If your plan covers Bijuva and your covered price is at or below $12.65, it does not exceed Mayne's more than $50 threshold for 30 capsules. The separate noncoverage trigger can still apply when the plan does not cover Bijuva at all.

Before opting out, compare the covered Extra Help price with the alternative-program quote. A State Health Insurance Assistance Program counselor or 1-800-MEDICARE can help you compare the Part D consequences without selling you a coupon.

Source: Medicare Extra Help costs for 2026.

What data does the Medicare form collect?

The enrollment form requests identity, birth date, address, email, and mobile number. It also states that de-identified redemption data may be collected, analyzed, and shared with Mayne for market research, while Mayne and InfinityRx may store personal and medical information for program administration.

That is not a reason to reject the program. It is a reason to read what you are consenting to before you submit the form.

Read the terms before you give up Part D credit. Review Mayne's Medicare program and opt-out language → Official manufacturer resource. This is not an affiliate link.

Does Bijuva have a generic or a cheaper FDA-approved option?

The FDA approved Amneal's 1 mg/100 mg estradiol-and-progesterone generic application on May 16, 2022 and found it bioequivalent and therapeutically equivalent to Bijuva 1 mg/100 mg. We did not verify a marketed Amneal version as of August 3, 2026. Other FDA-approved estrogen-and-progestogen prescriptions are different products, not automatic substitutes for Bijuva.

"No generic was ever approved" is wrong.

"A Bijuva generic is available at the pharmacy" is also wrong based on what we could verify.

What the FDA actually approved

Field	Verified FDA record
Applicant	Amneal Pharmaceuticals of New York, LLC
Application	ANDA 214293
Strength	Estradiol and progesterone capsules, 1 mg/100 mg
Approval date	May 16, 2022
Reference drug	Bijuva 1 mg/100 mg
FDA finding	Bioequivalent and therapeutically equivalent to Bijuva 1 mg/100 mg
Market status verified August 3, 2026	No marketed Amneal product was verified

Sources: FDA approval letter for ANDA 214293 and the FDA May 2022 Orange Book changes list, which marked the Amneal product as not being marketed.

The approval is for 1 mg/100 mg, not the 0.5 mg/100 mg strength.

Why approval did not produce a pharmacy product

TherapeuticsMD's public SEC filings describe a patent settlement that grants Amneal a license to commercialize its generic in the United States beginning in May 2032, or earlier under certain circumstances customary for that kind of settlement. FDA's approval letter lists Bijuva patents with November 21, 2032 expiration dates.

The accurate answer is:

A generic application was approved in 2022. No marketed generic was verified in August 2026. The settlement permits a May 2032 launch or an earlier launch if its specified circumstances occur.

Sources: TherapeuticsMD SEC filing describing the settlement and the FDA approval letter.

What other FDA-approved routes can a prescriber discuss?

Two categories may price differently under an individual plan:

• FDA-approved estradiol and progesterone prescribed as separate products
• Another FDA-approved estrogen/progestogen combination, such as estradiol/norethindrone acetate when clinically appropriate

Do not collapse those into "the same exact thing." They are different prescriptions, formulations, dosing decisions, and coverage paths. The Amneal ANDA is the FDA-rated generic equivalent of Bijuva 1 mg/100 mg; separately prescribed products are not.

The useful question is not "What can I substitute myself?" It is:

"Which FDA-approved option fits my clinical situation, and what does my plan charge for that exact prescription?"

This is a prescribing decision. Do not start, stop, split, or replace Bijuva on coupon information alone.

What do women actually say about paying for Bijuva?

Public comments about Bijuva often describe the exact moment behind this search: the prescription is ready, insurance has processed it, and the number is still painful. These are individual cost reports, not representative prices, medical evidence, or proof that any coupon will produce the same result for you.

Three short comments capture the friction:

"with insurance it's still $200/month."

"even with that it's still $75/Month."

"$250 is a car payment."

The first two appeared in a public Bijuva discussion on r/Menopause. The third came from a separate HRT affordability discussion. They are included for voice-of-customer context only—not efficacy, safety, or typical-cost evidence.

Sources: r/Menopause Bijuva discussion and r/Menopause HRT affordability discussion.

The emotion is not irrational. A difference between $35, $75, $200, and $250 every month is the difference between a manageable fill and walking away from the counter.

That is why this page refuses to hand you one borrowed number and call the job finished.

What did The HRT Index actually verify?

The HRT Index downloaded the current commercial card, reviewed the separate Medicare enrollment terms, inspected both sides of the manufacturer-linked BlinkRx flyer, checked the current FDA label and generic approval, read identified 2026 formulary and prior-authorization documents, and compared live coupon listings. Anything we could not establish from current source material is labeled instead of estimated.

What we read and when

Item	Source type	Date checked	Result
Commercial Bijuva copay card	Mayne manufacturer PDF	August 3, 2026	Current through December 31, 2026; commercial coverage required; no public fixed copay
Medicare Part D Alternative Coupon Program	Mayne enrollment page	August 3, 2026	Thresholds, calendar-year opt-out, no TrOOP/HSA/FSA submission, and maximum-limit terms verified
BlinkRx Bijuva delivery pricing	Manufacturer-linked two-page flyer	August 3, 2026	$25/$50 covered and $50 uncovered/cash displayed; back-page cash exclusion creates an unresolved conflict
GoodRx Prescription Services flyer	Manufacturer-linked price sheet	August 3, 2026	$25/$50 and $50 prices displayed, but the terms say the offer expired December 31, 2025
GoodRx manufacturer-coupon module	Third-party pricing page	August 3, 2026	$35/$75 claims, old phone, 2024 expiration, and use counts conflict with current manufacturer terms
Drugs.com and WebMDRx $35 statements	Secondary drug-price pages	August 3, 2026	$35 reported; no current Mayne document located that guarantees it
FDA Bijuva prescribing information	FDA label revised February 2026	August 3, 2026	Indication, strengths, evening-with-food dosing, boxed-warning removal, contraindications, and current warnings verified
Amneal generic application	FDA ANDA approval letter	August 3, 2026	1 mg/100 mg generic approved May 16, 2022; marketed product not verified
Patent settlement timing	TherapeuticsMD SEC filing	August 3, 2026	May 2032 license or earlier under specified customary circumstances
Express Scripts and Optum examples	Identified 2026 formulary documents	August 3, 2026	Excluded on one template; Tier 3 on another
Mass General Brigham criteria	Primary plan PA policy	August 3, 2026	Separate-agent response/intolerance/contraindication criterion verified for that plan policy
Cash-price snapshots	GoodRx and SingleCare	August 3, 2026	Exact prescription and channel documented; not presented as national guarantees

Published claim versus verified conclusion

Published claim	Source category	What we verified	Final language used on this page
Bijuva can cost $35 with the manufacturer card	Secondary coupon sites	The current Mayne retail card does not publish or guarantee $35	Secondary sites report $35; Mayne's current public terms do not promise it
Cash-paying patients can use the manufacturer card	Stale GoodRx module	Current retail terms exclude cash-paying patients	The commercial retail card cannot be used as a cash coupon
Bijuva has no generic	Consumer drug pages	FDA approved Amneal's 1 mg/100 mg ANDA in 2022, but no marketed product was verified	Approved, not verified as marketed
Bijuva is always excluded or always covered	Isolated formularies	Status differs by plan document	Check the exact plan; national templates are examples, not your answer
A rejected card means the program is expired	Pharmacy experience or stale listing	The current card expires December 31, 2026	Get the exact rejection and use the current card

The discrepancy log

These conflicts were live or publicly linked when we checked:

1. GoodRx shows a December 31, 2024 expiration; Mayne's current card says December 31, 2026.
2. GoodRx says insurance is not required; Mayne's retail card requires commercial coverage of Bijuva.
3. GoodRx lists a $75 cash/noncovered route; Mayne's retail card excludes cash-paying patients.
4. GoodRx, Drugs.com, and WebMDRx publish $35; Mayne's current public retail-card terms publish no fixed amount.
5. Mayne's BlinkRx flyer advertises $50 for uncovered and cash-pay patients on the front, then excludes cash-paying patients in the fine print on the back.
6. Mayne's HCP support page still links a GoodRx Prescription Services price sheet whose terms expired December 31, 2025.
7. Bijuva's manufacturer cost-and-savings page still displays older boxed-warning language, while the current FDA label says the boxed warning was removed in February 2026. The current contraindications and warnings still matter.
8. Consumer pages saying no generic was approved conflict with FDA's May 2022 ANDA approval.

What we could not verify—and will not guess at

• The fixed final price under the commercial retail card
• The maximum dollar benefit under either Mayne formal program
• The current number of permitted commercial-card uses
• A universal 90-day commercial-card benefit
• Universal mail-order acceptance of the retail card
• The final Medicare alternative-program price before approval and processing
• A clean cash-pay eligibility answer under the contradictory BlinkRx flyer
• A marketed Amneal Bijuva generic
• A separate current income-based Mayne patient assistance program for Bijuva
• Coverage or tier on any reader's individual plan

How The HRT Index works

This page was produced under The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule.

The five pillars stay in this order: clinical legitimacy, care quality, medication fit, price transparency, access.

On this page, that means:

• Clinical legitimacy: use the current FDA label, not stale marketing copy
• Care quality: give the reader accurate questions for the insurer, pharmacist, and prescriber
• Medication fit: never imply that coupon eligibility decides whether Bijuva is appropriate
• Price transparency: separate official terms, expired flyers, live screen prices, and unresolved conflicts
• Access: map commercial, Medicare, cash, delivery, denial, and alternative routes without pretending every route is open

Who created this: The HRT Index Editorial Team. How: by reading primary documents, comparing dated live listings, and preserving the conflicts instead of smoothing them over. Why: because a woman should not lose money—or abandon an active card—because one page copied a number from another.

What we did not do: we did not redeem the card, run a live pharmacy claim, enroll in the Medicare program, or receive a guaranteed quote from BlinkRx. If we had, we would say so.

When this page gets checked again

We re-check the commercial card, Medicare terms, delivery flyers, and live coupon conflicts monthly. FDA labeling, generic status, and identified formularies are checked quarterly and whenever a material change is announced. The December 31, 2026 commercial-card expiration is a hard update trigger.

What is Bijuva?

Bijuva is an FDA-approved oral capsule containing estradiol and progesterone. It is indicated for a woman with a uterus for treatment of moderate-to-severe vasomotor symptoms due to menopause. The current label lists 0.5 mg/100 mg and 1 mg/100 mg strengths taken as one capsule each evening with food.

That is enough medical context to make the cost page make sense.

What the current FDA label says

Label fact	Current FDA information
Product	Bijuva, estradiol and progesterone capsules for oral use
Initial U.S. approval	2018
Indication	Moderate-to-severe vasomotor symptoms due to menopause in a woman with a uterus
Strengths	0.5 mg estradiol/100 mg progesterone and 1 mg estradiol/100 mg progesterone
Administration	One capsule each evening with food
Boxed warning	Removed in February 2026
Safety after removal	Contraindications and warnings remain in the current prescribing information

Source: Current FDA Bijuva prescribing information.

The boxed-warning removal did not turn a prescription medication into a coupon decision. The current label still lists contraindications and warnings involving thromboembolic disease, malignant neoplasms, gallbladder disease, and other risks.

Four different parties make four different decisions:

• The prescriber decides whether Bijuva is appropriate.
• The insurer decides coverage under the plan.
• Mayne's program terms decide coupon eligibility.
• The pharmacy processes the transaction.

This page explains payment routes. It does not tell you to start, stop, replace, or change Bijuva.

What else should you know about the Bijuva savings card?

These answers close the eligibility, insurance, Medicare, pharmacy, expiration, and generic questions most likely to send you back to search. Each answer is based on current manufacturer terms, current FDA records, or a clearly labeled secondary price source. Where Mayne does not publish an answer, we say so.

Do I need to sign up for the Bijuva savings card?

The commercial retail card says it is activated and ready to use, and it does not show a separate patient enrollment form. The Medicare alternative program is different: it requires an enrollment form and participant attestations.

When does the Bijuva savings card expire?

The current commercial card expires December 31, 2026, unless Mayne rescinds, revokes, or amends the offer earlier. GoodRx's 2024 expiration is stale.

Does the Bijuva savings card guarantee $35?

No. GoodRx, Drugs.com, and WebMDRx publish $35, but Mayne's current retail-card terms say patient costs vary and maximum reimbursement limits apply without stating that amount.

Can I use the commercial card if insurance does not cover Bijuva?

No. The current retail-card terms require the commercial plan to cover the Bijuva prescription when it is filled and dispensed.

Can I use a Bijuva coupon without insurance?

Not the commercial retail card. Compare third-party cash prices and request a live delivery quote; do not treat the contradictory BlinkRx flyer as a guaranteed cash offer.

Can I use the commercial card with Medicare?

No. The commercial card excludes Medicare, Medicare Advantage, and Part D. The separate Medicare Part D Alternative Coupon Program has its own thresholds and calendar-year opt-out terms.

Can I use either Mayne program with Medicaid, TRICARE, VA, or IHS?

The commercial card excludes those government-funded programs. The Medicare alternative program also excludes people with prescription coverage under other federal or state health programs such as Medicaid or TRICARE.

Can I use the commercial card if I have an employer plan but am eligible for Medicare?

The current terms exclude a Medicare-eligible individual enrolled in an employer-sponsored health plan or retiree prescription-drug benefit. Confirm your benefit type with the administrator and InfinityRx before relying on the card.

Can I claim the Bijuva savings on an HSA or FSA?

For the commercial card, do not seek reimbursement for the value paid by the card. The terms do not say that every remaining patient-paid dollar is automatically ineligible, so ask the account administrator. The Medicare program is stricter and bars submitting its Bijuva out-of-pocket costs to an HSA, FSA, insurance plan, or other healthcare-reimbursement account.

Can I combine the card with GoodRx or SingleCare?

Not on the same prescription transaction. GoodRx and other cash discounts are alternatives to the insurance claim, and Mayne's Medicare program explicitly prohibits combining it with another coupon or prescription savings card.

Does the commercial card work after a prior-authorization denial?

Not while the plan is refusing coverage. Ask whether the denial can be appealed or corrected, and use the plan's written criteria rather than assuming a card can override it.

Can I use the card for a 90-day supply?

The current commercial card does not publish a universal 90-day benefit or current use count. The Medicare program has a 90-count entry threshold, but that does not establish the commercial-card reimbursement for a 90-day fill. Call 1-888-927-3499.

Can I use the commercial card through mail order?

The current retail-card terms specify participating U.S. retail pharmacies and do not establish universal mail-order acceptance. BlinkRx is a separate delivery route with separate materials and a live-quote process.

How many times can I use the commercial card?

Mayne's current card does not publish a use count. GoodRx lists 12 uses for 30-day fills and four for 90-day fills beside a stale 2024 expiration, so do not rely on those numbers without confirmation from InfinityRx.

Is there a Bijuva patient assistance program?

We found no separate income-based Bijuva patient assistance program in Mayne's current public Bijuva resources as of August 3, 2026. Because programs can change, confirm directly rather than treating that finding as permanent.

Who should I call if the card is rejected?

Call InfinityRx at 1-888-927-3499, ideally while the pharmacy claim is still open. Ask the pharmacist for the exact response or rejection code first.

Does Bijuva have a generic?

FDA approved Amneal's 1 mg/100 mg generic application in May 2022, but no marketed version was verified as of August 3, 2026. The patent settlement permits commercialization in May 2032 or earlier under specified circumstances.

Is the Bijuva card insurance?

No. Both Mayne formal programs state that the card or coupon is not insurance.

What should you do next?

The right next move depends on where the transaction broke: eligibility, coverage, Medicare rules, cash price, or prescription fit. Do not repeat the same failed route and hope the number changes. Use the row that matches what the insurer or pharmacy actually told you.

Where you landed	What to do now
Commercial plan covers Bijuva	Download the current card and compare insurance alone with insurance plus the card.
Commercial plan covers Bijuva and delivery appeals to you	Request a live BlinkRx quote before relying on the flyer or transferring solely for an advertised number.
Commercial plan says prior authorization is required	Get the written criteria and ask the prescriber to submit accurate clinical documentation.
Commercial plan excludes Bijuva	Ask for the exception process, compare an exact cash quote, and discuss another FDA-approved prescription if the denial remains.
Medicare Part D or Medicare Advantage	Review the thresholds, year-end opt-out, no-TrOOP term, and actual coupon quote before enrolling.
Extra Help and the plan covers Bijuva	Compare the covered brand copay—generally no more than $12.65 in 2026—with the program; the price-threshold route may not apply.
Uninsured or paying cash	Compare the exact 30-capsule prescription across cash and delivery channels. Confirm the BlinkRx result live.
Card rejected	Get the exact response, confirm the current card and Other Coverage Code, then call 1-888-927-3499.
Cost remains out of reach	Ask the prescriber which covered FDA-approved options fit your situation and what each exact prescription costs under the plan.

Still not sure which HRT program is right for you?

Take our free 90-second matching quiz. This page solved one narrow problem: the payment mechanics of a Bijuva savings route. Find My HRT Path handles the broader care decision and flags when an in-person clinician should be your starting point.

The HRT Index's Find My HRT Path tool gives you a personalized starting route, explains why it fits, shows backup options, and flags when online care is not the right first step. No email is required to see the result.

Get my personalized HRT starting-point plan →

---

The HRT Index is an independent decision resource. This article contains no paid provider link. Manufacturer, government, insurer, pharmacy, and pricing resources are linked so you can inspect the evidence, and The HRT Index earns nothing from those links. Our affiliate disclosure explains how the site is funded.

This page is educational research, not medical advice, and it is not medically reviewed by a clinician. A licensed clinician makes treatment decisions for an individual patient.

Last verified August 3, 2026. Program terms, prices, formularies, delivery routes, and FDA records can change. We re-check this page monthly and update the visible date only after material facts are verified.